{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T07:55:45Z","timestamp":1781510145094,"version":"3.54.1"},"reference-count":63,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"vor","delay-in-days":38,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Rheumatology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.berh.2026.102143","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T17:32:43Z","timestamp":1775151163000},"page":"102143","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["CAR T-cell therapy and indications for pediatric rheumatology"],"prefix":"10.1016","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9755-6851","authenticated-orcid":false,"given":"Kali","family":"Chiriboga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7092-8838","authenticated-orcid":false,"given":"Pooja N.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9478-2987","authenticated-orcid":false,"given":"Hermine I.","family":"Brunner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.berh.2026.102143_bib1","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/s41584-025-01272-3","article-title":"CAR T cell therapy for children with rheumatic disease: the time is now","volume":"21","author":"Wobma","year":"2025","journal-title":"Nat Rev Rheumatol Nat Res"},{"issue":"8","key":"10.1016\/j.berh.2026.102143_bib2","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-Cell therapy in autoimmune disease - a case series with Follow-up","volume":"390","author":"M\u00fcller","year":"2024","journal-title":"N Engl J Med"},{"issue":"10437","key":"10.1016\/j.berh.2026.102143_bib3","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/S0140-6736(24)00424-0","article-title":"CAR T-cell therapy rescues adolescent with rapidly progressive lupus nephritis from haemodialysis","volume":"403","author":"Krickau","year":"2024","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.berh.2026.102143_bib4","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s13075-025-03564-1","article-title":"CAR-T cell therapy for juvenile-onset autoimmune diseases: a promising future?","volume":"27","author":"Jouret","year":"2025","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.berh.2026.102143_bib5","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41571-018-0075-2","article-title":"Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy","volume":"16","author":"Mahadeo","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"9","key":"10.1016\/j.berh.2026.102143_bib6","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1200\/JCO.22.02345","article-title":"CAR T-Cells for cure in pediatric B-ALL","volume":"41","author":"Gardner","year":"2023","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.berh.2026.102143_bib7","first-page":"35","article-title":"Pediatric survivorship: considerations following CAR T-cell therapy","volume":"23","author":"Callahan","year":"2019","journal-title":"Clin J Oncol Nurs"},{"issue":"1","key":"10.1016\/j.berh.2026.102143_bib8","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jtct.2023.10.006","article-title":"INSPIRED symposium part 3: prevention and management of pediatric chimeric antigen receptor T cell-associated emergent toxicities","volume":"30","author":"McNerney","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"2","key":"10.1016\/j.berh.2026.102143_bib9","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s11912-024-01634-2","article-title":"Cardiotoxic effects following CAR-T cell therapy: a literature review","volume":"27","author":"Joseph","year":"2025","journal-title":"Curr Oncol Rep"},{"issue":"20","key":"10.1016\/j.berh.2026.102143_bib10","first-page":"2452","article-title":"How I approach optimization of patients at risk of cardiac and pulmonary complications after CAR T-cell therapy","volume":"141","author":"Gutierrez","year":"2023","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.berh.2026.102143_bib11","doi-asserted-by":"crossref","first-page":"3544","DOI":"10.1182\/bloodadvances.2024013243","article-title":"Risk of T-cell malignancy after CAR T-cell therapy in children, adolescents, and young adults","volume":"8","author":"Lamble","year":"2024","journal-title":"Blood Adv"},{"issue":"6","key":"10.1016\/j.berh.2026.102143_bib12","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: what we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.berh.2026.102143_bib13","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2024-210536","article-title":"Long-Term immunological consequences of CD19 CAR T cell therapy: analysis of infectious complications and immune reconstitution","volume":"144","author":"Riedel","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.berh.2026.102143_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1303935","article-title":"Lymphodepletion \u2013 an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle","volume":"14","author":"Lickefett","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.berh.2026.102143_bib15","article-title":"Prophylactic use of interleukin 6 monoclonal antibody can reduce CRS response of CAR-T cell therapy","volume":"10","author":"Dou","year":"2024","journal-title":"Front Front Med (Lausanne)"},{"issue":"10","key":"10.1016\/j.berh.2026.102143_bib16","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.jtct.2024.07.018","article-title":"Best practice considerations by the American society of transplant and cellular therapy: infection prevention and management after chimeric antigen receptor T cell therapy for hematological malignancies","volume":"30","author":"Shahid","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"2","key":"10.1016\/j.berh.2026.102143_bib17","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s15010-020-01521-5","article-title":"Recommendations for screening, monitoring, prevention, and prophylaxis of infections in adult and pediatric patients receiving CAR T-cell therapy: a position paper","volume":"49","author":"Los-Arcos","year":"2020","journal-title":"Infection"},{"key":"10.1016\/j.berh.2026.102143_bib18","author":"Barz Leahy"},{"issue":"1","key":"10.1016\/j.berh.2026.102143_bib19","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-020-02292-y","article-title":"Ovarian dysfunction with moderate-dose intravenous cyclophosphamide (modified NIH regimen) and mycophenolate mofetil in young adults with severe lupus: a prospective cohort study","volume":"22","author":"Sharma","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.berh.2026.102143_bib20","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/978-3-031-76882-8_51","article-title":"Post-treatment surveillance for pediatric cancer patients","author":"Khan","year":"2025","journal-title":"Pediatr Surg Oncol"},{"issue":"15_suppl","key":"10.1016\/j.berh.2026.102143_bib21","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.10531","article-title":"Cardiac effects of chimeric antigen receptor (CAR) T-cell therapy in children","volume":"35","author":"Burstein","year":"2017","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.berh.2026.102143_bib22","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1002\/art.34472","article-title":"Prevalence, incidence, and demographics of systemic lupus erythematosus and lupus nephritis from 2000 to 2004 among children in the US Medicaid beneficiary population","volume":"64","author":"Hiraki","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.berh.2026.102143_bib23","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1191\/0961203303lu469xx","article-title":"Epidemiology of systemic lupus erythematosus in a northern Spanish population: gender and age influence on immunological features","volume":"12","author":"L\u00f3pez","year":"2003","journal-title":"Lupus"},{"issue":"2","key":"10.1016\/j.berh.2026.102143_bib24","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1002\/art.23204","article-title":"Difference in disease features between childhood-onset and adult-onset systemic lupus erythematosus","volume":"58","author":"Brunner","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2026.102143_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1128754","article-title":"Childhood-onset systemic lupus erythematosus: characteristics and the prospect of glucocorticoid pulse therapy","volume":"14","author":"Pan","year":"2023","journal-title":"Front Immunol"},{"issue":"8","key":"10.1016\/j.berh.2026.102143_bib26","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1002\/art.40512","article-title":"Brief report: Lupus-An unrecognized leading cause of death in young females: a population-based study using nationwide death certificates, 2000-2015","volume":"70","author":"Yen","year":"2018","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"10.1016\/j.berh.2026.102143_bib27","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1053\/j.ajkd.2021.07.013","article-title":"Dialysis outcomes for children with lupus nephritis compared to children with other forms of nephritis: a retrospective cohort study","volume":"79","author":"Wasik","year":"2022","journal-title":"Am J Kidney Dis"},{"issue":"482","key":"10.1016\/j.berh.2026.102143_bib28","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aav1648","article-title":"Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus","volume":"11","author":"Kansal","year":"2019","journal-title":"Sci Transl Med"},{"issue":"3","key":"10.1016\/j.berh.2026.102143_bib29","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.semarthrit.2012.05.001","article-title":"Differences in autoantibody profiles and disease activity and damage scores between Childhood- and adult-onset systemic lupus erythematosus: a meta-analysis","volume":"42","author":"Livingston","year":"2012","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.berh.2026.102143_bib30","first-page":"1","article-title":"CAR T cells in pediatric systemic lupus erythematosus","author":"Simopoulou","year":"2025","journal-title":"Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.berh.2026.102143_bib31","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1093\/rheumatology\/keu289","article-title":"Incidence and prevalence of inflammatory myopathies: a systematic review","volume":"54","author":"Meyer","year":"2015","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"10.1016\/j.berh.2026.102143_bib32","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1093\/rheumatology\/kel025","article-title":"An international consensus survey of the diagnostic criteria for juvenile dermatomyositis (JDM)","volume":"45","author":"Brown","year":"2006","journal-title":"Rheumatology"},{"issue":"1","key":"10.1016\/j.berh.2026.102143_bib33","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s40272-024-00658-2","article-title":"Juvenile dermatomyositis: updates in pathogenesis and biomarkers, Current treatment, and emerging targeted therapies","volume":"27","author":"Kim","year":"2025","journal-title":"Pediatric drugs Adis"},{"issue":"5","key":"10.1016\/j.berh.2026.102143_bib34","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/s41577-022-00787-0","article-title":"Neutrophil extracellular traps in systemic autoimmune and autoinflammatory diseases","volume":"23","author":"Wigerblad","year":"2023","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"10.1016\/j.berh.2026.102143_bib35","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/s41584-023-00967-9","article-title":"Juvenile idiopathic inflammatory myositis: an update on pathophysiology and clinical care","volume":"19","author":"Papadopoulou","year":"2023","journal-title":"Nat Rev Rheumatol"},{"issue":"10","key":"10.1016\/j.berh.2026.102143_bib36","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/art.42933","article-title":"Autologous CD19-Targeting CAR T cells in a patient with refractory juvenile dermatomyositis","volume":"76","author":"Nicolai","year":"2024","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.berh.2026.102143_bib37","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3899\/jrheum.160688","article-title":"Childhood arthritis and rheumatology research alliance consensus clinical treatment plans for juvenile dermatomyositis with persistent skin rash","volume":"44","author":"Huber","year":"2017","journal-title":"J Rheumatol"},{"key":"10.1016\/j.berh.2026.102143_bib38","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/acr.20071","article-title":"Protocols for the initial treatment of moderately severe juvenile dermatomyositis: results of a children's arthritis and rheumatology research alliance consensus conference","volume":"62","author":"Huber","year":"2010","journal-title":"Arthritis Care Res"},{"issue":"1","key":"10.1016\/j.berh.2026.102143_bib39","doi-asserted-by":"crossref","DOI":"10.1186\/s12969-016-0134-0","article-title":"Childhood arthritis and rheumatology research alliance consensus clinical treatment plans for juvenile dermatomyositis with skin predominant disease","volume":"15","author":"Kim","year":"2017","journal-title":"Pediatr Rheumatol"},{"issue":"4","key":"10.1016\/j.berh.2026.102143_bib40","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1002\/acr.20695","article-title":"Consensus treatments for moderate juvenile dermatomyositis: beyond the first two months. Results of the second childhood arthritis and rheumatology research alliance consensus conference","volume":"64","author":"Huber","year":"2012","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.berh.2026.102143_bib41","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/acr.20071","article-title":"Protocols for the initial treatment of moderately severe juvenile dermatomyositis: results of a children's arthritis and rheumatology research alliance consensus conference","volume":"62","author":"Huber","year":"2010","journal-title":"Arthritis Care Res"},{"issue":"4","key":"10.1016\/j.berh.2026.102143_bib42","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1002\/acr.20695","article-title":"Consensus treatments for moderate juvenile dermatomyositis: beyond the first two months. Results of the second childhood arthritis and rheumatology research alliance consensus conference","volume":"64","author":"Huber","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"10.1016\/j.berh.2026.102143_bib43","doi-asserted-by":"crossref","DOI":"10.1186\/s12969-016-0134-0","article-title":"Childhood arthritis and rheumatology research alliance consensus clinical treatment plans for juvenile dermatomyositis with skin predominant disease","volume":"15","author":"Kim","year":"2017","journal-title":"Pediatr Rheumatol"},{"key":"10.1016\/j.berh.2026.102143_bib44","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.curtheres.2018.12.001","article-title":"Pediatric drug development: challenges and opportunities","volume":"90","author":"Spadoni","year":"2019","journal-title":"Curr Ther Res Clin Exp"},{"issue":"2","key":"10.1016\/j.berh.2026.102143_bib45","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/art.37754","article-title":"Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo\u2010phase trial","volume":"65","author":"Oddis","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.berh.2026.102143_bib46","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.kint.2019.12.025","article-title":"Anti-CD20\u2013mediated B-cell depletion in autoimmune diseases: successes, failures and future perspectives","volume":"97","author":"Crickx","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.berh.2026.102143_bib47","article-title":"B cell depletion therapies in autoimmune diseases: monoclonal antibodies or chimeric antigen receptor-based therapy?","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.berh.2026.102143_bib48","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1051609","article-title":"Efficacy and safety of rituximab treatment in patients with idiopathic inflammatory myopathies: a systematic review and meta-analysis","volume":"13","author":"Zhen","year":"2022","journal-title":"Front Immunol"},{"issue":"10416","key":"10.1016\/j.berh.2026.102143_bib49","first-page":"2034","article-title":"CAR T-cell therapy in autoimmune diseases","volume":"402","author":"Schett","year":"2023","journal-title":"Lancet Elsevier B V"},{"issue":"2","key":"10.1016\/j.berh.2026.102143_bib50","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1177\/2397198318763701","article-title":"Assessing the prevalence of juvenile systemic sclerosis in childhood using administrative claims data from the United States","volume":"3","author":"Beukelman","year":"2018","journal-title":"J Scleroderma Relat Disord"},{"issue":"4","key":"10.1016\/j.berh.2026.102143_bib51","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1080\/1744666X.2023.2298354","article-title":"Best clinical practice in the treatment of juvenile systemic sclerosis: expert panel guidance - the result of the international Hamburg consensus meeting December 2022","volume":"20","author":"Foeldvari","year":"2024","journal-title":"Expet Rev Clin Immunol"},{"key":"10.1016\/j.berh.2026.102143_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2023.152197","article-title":"Juvenile and adult-onset scleroderma: different clinical phenotypes","volume":"60","author":"Adrovic","year":"2023","journal-title":"Semin Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.berh.2026.102143_bib53","first-page":"757","article-title":"Scleroderma in children and adolescents","volume":"65","author":"Li","year":"2018","journal-title":"Pediatr Clin"},{"issue":"1","key":"10.1016\/j.berh.2026.102143_bib54","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12969-025-01100-8","article-title":"Developing consensus outcome measures in juvenile systemic sclerosis: a global survey of pediatric rheumatologists and literature review","volume":"23","author":"Vasquez-Canizares","year":"2025","journal-title":"Pediatr Rheumatol"},{"issue":"12","key":"10.1016\/j.berh.2026.102143_bib55","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1002\/acr.23547","article-title":"Clinical characteristics and factors associated with disability and impaired quality of life in children with juvenile systemic sclerosis: results from the childhood arthritis and rheumatology research alliance legacy registry","volume":"70","author":"Stevens","year":"2018","journal-title":"Arthritis Care Res"},{"issue":"2","key":"10.1016\/j.berh.2026.102143_bib56","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/rheumatology\/ken388","article-title":"Factors affecting survival in juvenile systemic sclerosis","volume":"48","author":"Martini","year":"2009","journal-title":"Rheumatology"},{"issue":"12","key":"10.1016\/j.berh.2026.102143_bib57","doi-asserted-by":"crossref","first-page":"3971","DOI":"10.1002\/art.22207","article-title":"Systemic sclerosis in childhood: clinical and immunologic features of 153 patients in an international database","volume":"54","author":"Martini","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.berh.2026.102143_bib58","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1093\/rheumatology\/39.5.556","article-title":"Favourable outcome in 135 children with juvenile systemic sclerosis: results of a multi-national survey","volume":"39","author":"Foeldvari","year":"2000","journal-title":"Rheumatology"},{"issue":"5","key":"10.1016\/j.berh.2026.102143_bib59","first-page":"1004","article-title":"Childhood onset systemic sclerosis: classification, clinical and serologic features, and survival in comparison with adult onset disease","volume":"33","author":"Scalapino","year":"2006","journal-title":"J Rheumatol"},{"issue":"5","key":"10.1016\/j.berh.2026.102143_bib60","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1097\/BOR.0b013e3283103cfd","article-title":"Update on pediatric systemic sclerosis: similarities and differences from adult disease","volume":"20","author":"Foeldvari","year":"2008","journal-title":"Curr Opin Rheumatol"},{"issue":"1","key":"10.1016\/j.berh.2026.102143_bib61","article-title":"Pulmonary manifestations of juvenile vs. adult systemic sclerosis: insights into pathophysiological and clinical features","volume":"60","author":"Di","year":"2025","journal-title":"Pediatr Pulmonol"},{"issue":"4","key":"10.1016\/j.berh.2026.102143_bib62","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1080\/1744666X.2025.2474216","article-title":"Guidance for stem cell therapy for juvenile systemic sclerosis patients","volume":"21","author":"Foeldvari","year":"2025","journal-title":"Expet Rev Clin Immunol"},{"issue":"10","key":"10.1016\/j.berh.2026.102143_bib63","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1016\/j.clinthera.2017.09.001","article-title":"Roles of clinical research networks in pediatric drug development","volume":"39","author":"Turner","year":"2017","journal-title":"Clin Ther"}],"container-title":["Best Practice & Research Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694226000288?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694226000288?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T07:45:41Z","timestamp":1781509541000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521694226000288"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":63,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S1521694226000288"],"URL":"https:\/\/doi.org\/10.1016\/j.berh.2026.102143","relation":{},"ISSN":["1521-6942"],"issn-type":[{"value":"1521-6942","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CAR T-cell therapy and indications for pediatric rheumatology","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Rheumatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.berh.2026.102143","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102143"}}